UBS Group
MGX icon

UBS Group’s Metagenomi Therapeutics MGX Stock Holding History

UBS Group’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.8K Sell
15,793
-305
-2% -$408 ﹤0.01% 8195
2026
Q1 		$21.6K Sell
16,098
-9,001
-36% -$14K ﹤0.01% 7883
2025
Q4 		$40.7K Buy
25,099
+1,611
+7% +$3.49K ﹤0.01% 7331
2025
Q3 		$55.7K Sell
23,488
-95,433
-80% -$194K ﹤0.01% 7482
2025
Q2 		$176K Buy
118,921
+51,170
+76% +$80.1K ﹤0.01% 6807
2025
Q1 		$92.1K Buy
67,751
+28,701
+73% +$68.4K ﹤0.01% 7103
2024
Q4 		$141K Buy
39,050
+29,989
+331% +$72.4K ﹤0.01% 6668
2024
Q3 		$19.7K Buy
9,061
+6,903
+320% +$23.9K ﹤0.01% 7386
2024
Q2 		$8.8K Buy
2,158
+478
+28% +$3.28K ﹤0.01% 7778
2024
Q1 		$17.7K Buy
+1,680
New +$19.3K ﹤0.01% 6977

Other funds holding MGX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group's MGX Position: Q2 2026 in Review

UBS Group reduced its Metagenomi Therapeutics (MGX) stake by 1.9% in Q2 2026, selling an estimated $408 and leaving 15,793 shares worth $18.8K. The position accounts for ﹤0.01% of the portfolio, ranked #8195.

UBS Group first reported a position in MGX in Q1 2024 and has held it in 10 quarters since. The position peaked at $176K in Q2 2025. 43 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

  • UBS Group held 15,793 shares of Metagenomi Therapeutics worth $18.8K as of Q2 2026.
  • UBS Group sold 305 Metagenomi Therapeutics shares in Q2 2026, an estimated $408.
  • Metagenomi Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8195 holding.
  • UBS Group first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • UBS Group's Metagenomi Therapeutics position peaked at $176K in Q2 2025.
  • 43 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.